Core Insights - Seer, Inc. will report its financial results for Q3 2025 on November 6, 2025, with a conference call scheduled for 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time [1] Company Overview - Seer, Inc. is a leader in deep, unbiased proteomics, providing insights that are scalable, fast, precise, and reproducible, which are not achievable by traditional proteomic methods [3] - The company's Proteograph Product Suite integrates proprietary engineered nanoparticles, streamlined automation, optimized consumables, and advanced analytical software to address challenges faced by conventional proteomic technologies [3] - Seer's products are intended for research use only and are not designed for diagnostic procedures [3]

Core Insights - Seer, Inc. is participating in the ASHG 2025 Annual Meeting, highlighting the importance of proteomics in complementing genomics for understanding disease biology and advancing precision medicine [1][5] - The Proteograph Product Suite is showcased as a transformative tool in multi-omic approaches, enabling researchers to derive clinical insights from genomic data [2][4] Company Overview - Seer, Inc. sets a high standard in deep, unbiased proteomics, offering insights that are scalable, precise, and reproducible, which traditional methods have struggled to achieve [6][8] - The company integrates engineered nanoparticles, automation instrumentation, consumables, and analytical software to address challenges faced by conventional proteomic technologies [6][8] Scientific Contributions - Multiple independent research groups will present findings using Seer's Proteograph platform, indicating its growing adoption in academic and clinical settings [4] - Presentations will cover topics such as immune dynamics in xenotransplantation and isoform-specific biomarkers in idiopathic pulmonary fibrosis, showcasing the platform's ability to enhance disease discovery [6][7] Event Details - A featured CoLab session titled "Advancing Precision Medicine Through Multi-Omics" will take place on October 16, 2025, emphasizing the impact of Seer's technology on translational genomics [2] - Additional presentations will include topics on proteogenomic prioritization and high-confidence protein targets, further illustrating the breadth of research enabled by Seer's platform [7]

PresentationYuko OkuEquity Analyst Hi. My name is Yuko Oku and I'm part of the life science tools and diagnostics team at Morgan Stanley. Before we begin, I'd like to remind our listeners that important disclosure information can be found at morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales rep. With that, it's my pleasure to host Seer, and speaking on behalf of the company, CEO, Omid Farokhzad. Thank you for joining us today. ...

PresentationYuko OkuEquity Analyst Hi. My name is Yuko Oku and I'm part of the life science tools and diagnostics team at Morgan Stanley. Before we begin, I'd like to remind our listeners that important disclosure information can be found at morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales rep. With that, it's my pleasure to host Seer, and speaking on behalf of the company, CEO, Omid Farokhzad. Thank you for joining us today. ...

Summary of Seer Conference Call Company Overview - **Company**: Seer - **Industry**: Life Sciences Tools and Diagnostics Key Points and Arguments Product Development and Market Position - Seer has made significant progress in increasing awareness of the Proteograph Product Suite, with over 52 preprints and publications from the scientific community [3] - The latest product, Proteograph One, was released in June 2025, enabling large-scale proteomics [3] - Seer has secured corporate customers for large-scale studies, including a 10,000-sample study and a 20,000-sample study with Korea University [4] - The shift in customer discussions indicates a move from proof-of-principle studies to larger sample sizes, reflecting increased confidence in Seer's technology [5] Competitive Landscape - Emerging competitors in the proteomics space include OLINK, SomaLogic, Alamar, Quanterix, BGI, and PreOmics [6] - Seer differentiates itself by offering untargeted proteomics at scale, which was previously only available through targeted approaches [7] - The conversation has shifted from comparing Seer with multiple competitors to a more direct comparison with OLINK, indicating Seer's growing market presence [8] Customer Insights and Adoption - Customers are increasingly adopting Seer's technology for discovery purposes, moving away from initial skepticism [5] - The value of Seer's technology is highlighted by the high cost of biological samples, making the choice of proteomics platform critical for customers [11] - Comparative studies published by customers demonstrate Seer's superior performance in terms of depth of coverage and reproducibility [12] Product Innovations - The Proteograph XT and Proteograph One have improved throughput and reduced runtime, with Proteograph One capable of processing 1,000 samples per week [25] - The introduction of the Proteograph Direct Assay allows for analysis of cell and tissue samples without the need for proprietary nanoparticles, broadening the instrument's utility [21] - Seer's technology allows for the capture of post-translational modifications (PTMs), which is a unique selling point [24] Financial Health and Capital Allocation - Seer ended Q2 with $263 million in cash and a disciplined approach to capital allocation, focusing on share buybacks and internal investments [44] - A $25 million share buyback program has been authorized, with $20 million already executed [46] Market Trends and Future Outlook - The macro environment for life science tools remains challenging, with volatility affecting customer decision-making [41] - Seer anticipates continued growth in large-scale studies, predicting the initiation of 100,000-sample studies by 2026 [40] - The company is positioned to lead in both discovery and clinical applications of proteomics, with a focus on untargeted approaches for content discovery [48] Conclusion - Seer is well-positioned in the proteomics market with innovative products, a strong financial position, and a growing customer base. The company is focused on expanding its offerings and maintaining its competitive edge in a challenging macro environment.

Core Insights - Seer, Inc. has appointed Isaac Ro to its Board of Directors, enhancing its leadership team with expertise in financial leadership and life sciences [1][2] Company Overview - Seer, Inc. specializes in deep, unbiased proteomics, providing insights with scale, speed, precision, and reproducibility [4] - The company’s Proteograph Product Suite integrates engineered nanoparticles, automation instrumentation, consumables, and analytical software to address challenges faced by traditional proteomic technologies [4] Leadership and Experience - Isaac Ro is a Partner at Catalio Capital Management, with a history of leading investments in life science companies and serving on various boards [2] - Ro has previously held significant roles, including Executive Chairman of Haystack Oncology and Chief Financial Officer at Sema4 and Thrive Earlier Detection, guiding these companies through key transitions and acquisitions [2]

REDWOOD CITY, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the company will be participating in the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY. Seer’s management is scheduled to participate in a fireside chat on Tuesday, September 9th at 12:20 p.m. Eastern Time / 9:20 a.m. Pacific Time. A live webcast of the session will be available on the Investor sectio ...

Summary of SEER (SEER) FY Conference Call - August 13, 2025 Company Overview - SEER has been public since December 2020 and focuses on enabling access to proteomic content at unprecedented scale, speed, and cost [2][3] - The company offers the Proteograph product suite, which includes an instrument, consumable kits, and software for analysis [5] Core Product Developments - The initial version of the Proteograph could process 16 samples in eight hours, while the Protograph XT increased capacity to 40 samples in the same timeframe, reducing mass spectrometry time by 150% [6] - The latest product, Protograph One, launched in June 2025, allows for large population-scale proteomics, with a 10,000-sample study announced in Q1 and a 20,000-sample study in Q2 [7][8] Market Potential and Predictions - The CEO predicts that 2025 will be a pivotal year for population-scale proteomics, with expectations for a 100,000-sample study by 2026 [8] - The proteomic market is expected to expand significantly as access to the proteome becomes more feasible, similar to the genomic market's evolution [10][11] Challenges and Innovations - Historical bottlenecks in proteomics included the scalability of mass spectrometry and the complexity of the proteome, which SEER aims to address with its technology [13][14] - SEER has invested heavily in data analysis capabilities to overcome data bottlenecks created by increased sample sizes [16] Competitive Landscape - SEER's unique approach allows for unbiased proteomic analysis, which is expected to create new markets and expand existing ones [11][20] - The company holds over 250 patents, indicating a strong position in the proteomics field despite emerging competitors [31] Revenue Model and Financial Outlook - SEER's revenue is currently derived from consumables (65%), the SEER Technology Access Center (25%), and instruments (10-15%) [40] - The company has approximately $260 million in cash with no debt, projecting a burn rate that allows for 6-7 years of operation without needing additional capital [52][53] - A stock buyback program has been initiated, reflecting confidence in the company's value proposition [53] Customer Engagement and Market Strategy - SEER aims to be a tools provider rather than a service business, focusing on partnerships with customers and CROs [33][41] - The SEER Technology Access Center and Strategic Instrument Placement programs have been crucial in driving customer engagement and facilitating data generation [37][39] Future Expectations - The academic and government sectors are expected to remain significant revenue sources, with biopharma showing potential for growth as customers recognize the value of SEER's offerings [46][48] - The company anticipates continued innovation and investment in its product line to maintain a competitive edge in the proteomics market [54][55]

Group 1: Earnings Performance - Seer, Inc. reported a quarterly loss of $0.33 per share, better than the Zacks Consensus Estimate of a loss of $0.39, and compared to a loss of $0.35 per share a year ago, representing an earnings surprise of +15.38% [1] - The company posted revenues of $4.05 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 8.90%, and up from $3.07 million in the same quarter last year [2] - Over the last four quarters, Seer has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Group 2: Stock Performance and Outlook - Seer shares have declined approximately 8.2% since the beginning of the year, while the S&P 500 has gained 7.1% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.19 on revenues of $4.32 million, and for the current fiscal year, it is -$1.05 on revenues of $17.54 million [7] - The estimate revisions trend for Seer was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Group 3: Industry Context - The Medical - Biomedical and Genetics industry, to which Seer belongs, is currently ranked in the bottom 42% of over 250 Zacks industries, suggesting potential challenges for stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Financial Data and Key Metrics Changes - SEER reported revenue of $4.1 million for Q2 2025, representing a 32% year-over-year growth from $3.1 million in Q2 2024 [8][27] - The company ended the quarter with approximately $263 million in cash, cash equivalents, and investments, indicating a strong balance sheet [8][32] - The net loss for Q2 2025 was $19.4 million, an improvement from a net loss of $22.9 million in Q2 2024 [31] Business Line Data and Key Metrics Changes - Product revenue for Q2 2025 was $2.7 million, primarily from sales of Proteograph instruments and consumable kits [27] - Service revenue was $1.2 million, including $409,000 from related party revenue, mainly from STACK service projects [28] - Gross profit for Q2 2025 was $2.1 million, with a gross margin of 52%, down from 56% in Q2 2024 [29] Market Data and Key Metrics Changes - SEER's revenue guidance for the full year 2025 is projected to be between $17 million and $18 million, reflecting a 24% year-over-year growth at the midpoint [33] - The company noted that approximately 30% of its revenue exposure comes from academic and government entities, which may be impacted by funding changes [34] Company Strategy and Development Direction - SEER is focused on advancing four core growth catalysts for 2025, including validating its platform, enhancing access, driving innovation, and enabling larger cohort studies [10][37] - The launch of the Proteograph One workflow and SP200 automation instrument is seen as a transformative step for the field of proteomics, enabling larger studies and increasing throughput [11][12] Management's Comments on Operating Environment and Future Outlook - Management acknowledged near-term macro pressures, including evolving tariffs and uncertainty around government funding, which may affect market visibility [9][35] - Despite these challenges, management remains confident in the company's strong performance and reaffirmed its revenue guidance for 2025 [10][35] Other Important Information - SEER has repurchased approximately 10.7 million Class A common shares, reducing total shares outstanding by about 13% [32] - The company continues to see strong demand for its STACK program, which lowers barriers to adoption of the Proteograph product suite [22] Q&A Session Summary Question: Early feedback on the new Proteograph One assay - Management reported fantastic feedback on the Proteograph One assay, highlighting its ability to enable large-scale studies and improve throughput [41][44] Question: Pipeline of potential customers using the STACK program - Management indicated that a majority of instrument shipments in the first half of the year were to former STACK customers, and they expect this trend to continue [45][48] Question: Revenue from the co-marketing partnership with Thermo - Management noted that revenue from the Thermo partnership is still modest but expected to pick up in the second half of the year as the sales force has been fully trained [51][52] Question: Competitive landscape in proteomics - Management discussed the competitive landscape, emphasizing SEER's unique position in unbiased proteomics and the ability to conduct large-scale studies that were previously not possible [56][60]